<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> on day 1 of every 14-day cycle </plain></SENT>
<SENT sid="1" pm="."><plain>Nine patients were treated at 2 different cohort dose levels of drozitumab </plain></SENT>
<SENT sid="2" pm="."><plain>No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached </plain></SENT>
<SENT sid="3" pm="."><plain>Two patients had a partial response of 4.93 and 4.96 months duration </plain></SENT>
<SENT sid="4" pm="."><plain>Cohort 2 dose level is the recommended starting dose level for future trials </plain></SENT>
</text></document>